What Types of Cancer are Targeted by Proteasome Inhibitors?
Proteasome inhibitors have shown efficacy in treating several types of cancer, particularly multiple myeloma and certain types of lymphoma. For instance, Bortezomib, one of the first proteasome inhibitors to be approved by the FDA, has been used effectively to treat multiple myeloma. Other cancers that may respond to these inhibitors include mantle cell lymphoma and Waldenström's macroglobulinemia. Research is ongoing to explore the use of proteasome inhibitors in other cancer types.
